Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

0.0%

0 terminated out of 18 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

39%

7 trials in Phase 3/4

Results Transparency

56%

9 of 16 completed with results

Key Signals

9 with results100% success

Data Visualizations

Phase Distribution

13Total
P 2 (6)
P 3 (6)
P 4 (1)

Trial Status

Completed16
Withdrawn1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 16 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT01830868CompletedPrimary

A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)

NCT04252846Completed

A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

NCT03288129Phase 4CompletedPrimary

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

NCT03201900Phase 3CompletedPrimary

Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)

NCT01338805Phase 2CompletedPrimary

Phase II BGG492 Capsule Extension for Partial Epilepsy

NCT03836924CompletedPrimary

A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older

NCT02072824Phase 3CompletedPrimary

A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.

NCT01147003Phase 2CompletedPrimary

Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures

NCT01871233UnknownPrimary

An Extended Access Program for Perampanel

NCT01051193Phase 2CompletedPrimary

Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures

NCT00655486Phase 3Completed

Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures

NCT00655551Phase 3Completed

Safety of Intravenous Lacosamide Dose Followed by Twice Daily Oral Lacosamide in Subjects With Partial-onset Seizures

NCT01710657Phase 3Completed

A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures

NCT01506882Phase 3Completed

An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy

NCT01830400CompletedPrimary

A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)

NCT00975715Phase 2CompletedPrimary

Efficacy, Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures

NCT01407523Phase 2Completed

An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures

NCT01167335Phase 2WithdrawnPrimary

Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures

Showing all 18 trials

Research Network

Activity Timeline